Paul Caldron, DO, FACP, FACR, is a United States trained physician certified in internal medicine, rheumatology and geriatric medicine and is former CEO of the largest rheumatology group in the southwestern United States. He has been principal or sub-investigator on numerous pharmaceutical trials in the field of rheumatology. Dr. Caldron completed business training for an MBA degree at the top ranked Thunderbird School of Global Management in Arizona, USA.
Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R, Mazurov V, Bell M, Caldron P, Pillai L, Burnett BP. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther. 27(10):731-742, 2010.
Barry S. Skikne, Kari Punnonen, Paul H. Caldron, Michael T. Bennett, Mari Ervasti, Gail H. Gasior, Janna S. Chamberlin, Linda A. Sullivan, Kurtis R. Bray, Paula C. Southwick. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor (sTfR) and the sTfR / log ferritin index (sTfR Index). Am. J. Hematol. 86:923–927, 2011.
Paul H. Caldron. Russians Mourn Iconic Rheumatologist: Valentina A. Nasonova, MD, was Renaissance figure in Russian rheumatology. The Rheumatologist, May 2011. 14-16.
Caldron PH, Gavrilova SI, Kropf S. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world. Drug Design, Development and Therapy 2012:6 53–60.